Kröger N, Krüger W, Wacker-Backhaus G, Hegewisch-Becker S, Stockschläder M, Fuchs N, Rüssmann B, Renges H, Dürken M, Bielack S, de Wit M, Schuch G, Bartels H, Braumann D, Kuse R, Kabisch H, Erttmann R, Zander A R
Bone Marrow Transplantation Center and Department of Oncology/Hematology, University-Hospital Hamburg-Eppendorf, Hamburg, Germany.
Bone Marrow Transplant. 1998 Dec;22(11):1029-33. doi: 10.1038/sj.bmt.1701498.
We investigated an intensified conditioning regimen including fractionated total body irradiation (12 Gy), etoposide (30-45 mg/kg) and cyclophosphamide (120 mg/kg), followed by autologous (n = 5), allo-related (n = 13) or allo-unrelated (n = 6) bone marrow (n = 22) or peripheral stem cell (n = 2) transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. One patient received busulfan (16 mg/kg) instead of TBI. Nineteen patients were transplanted in 1CR, two in 2CR, one in 1PR and two in relapse. Major toxicity was mucositis grade II according to the Bearman scale in all patients. The treatment-related mortality was 25%, mainly due to infection or GVHD after allogeneic transplantation. After a median follow-up of 45 months (range 2-93), nine patients (37.5%) remain alive in CR. Nine patients (37.5%) relapsed and eight (33.3%) of these subsequently died. After autologous transplantation, four of five patients (80%) relapsed and died. Late relapse was seen after allogeneic, as well as autologous transplantation, at 33 and 59 months, respectively. The Kaplan-Meier estimate of leukemia-free survival for all patients is 38% at 3 years (95% CI: 18-58%) and 35% at 5 years (95% CI: 15-55%). For allogeneic transplants in first CR (n = 15) the estimate of disease-free survival was 46% at 3 years (95% CI: 19-73%) and 34% at 5 years (95% CI: 17-51%). Patients aged below 30 years had a better estimated overall survival at 3 years (61% vs 11%, P < 0.001). The bcr-abl fusion transcript (p210 vs p190 vs p210/190) did not affect disease-free or overall survival. In our experience, an intensified conditioning regimen seems to improve the results of bone marrow transplantation in patients with Ph+ acute lymphoblastic leukemia. However, the high relapse rate warrants novel approaches to enhance anti-leukemic efficacy.
我们研究了一种强化预处理方案,包括分次全身照射(12 Gy)、依托泊苷(30 - 45 mg/kg)和环磷酰胺(120 mg/kg),随后对费城染色体阳性急性淋巴细胞白血病患者进行自体(n = 5)、亲缘异体(n = 13)或非亲缘异体(n = 6)骨髓(n = 22)或外周干细胞(n = 2)移植。1例患者接受白消安(16 mg/kg)替代全身照射。19例患者在第1次完全缓解(1CR)时进行移植,2例在第2次完全缓解(2CR)时移植,1例在第1次部分缓解(1PR)时移植,2例在复发时移植。根据贝尔曼量表,所有患者的主要毒性为II级黏膜炎。治疗相关死亡率为25%,主要由于异基因移植后的感染或移植物抗宿主病(GVHD)。中位随访45个月(范围2 - 93个月)后,9例患者(37.5%)仍处于完全缓解状态存活。9例患者(37.5%)复发,其中8例(33.3%)随后死亡。自体移植后,5例患者中有4例(80%)复发并死亡。异基因移植和自体移植后均出现晚期复发,分别在33个月和59个月。所有患者无白血病生存的Kaplan - Meier估计值在3年时为38%(95%可信区间:18 - 58%),5年时为35%(95%可信区间:15 - 55%)。对于首次完全缓解时进行异基因移植的患者(n = 15),无病生存估计值在3年时为46%(95%可信区间:19 - 73%),5年时为34%(95%可信区间:17 - 51%)。年龄低于30岁的患者3年总生存估计值更好(61%对11%,P < 0.001)。bcr - abl融合转录本(p210对p190对p210/190)不影响无病生存或总生存。根据我们的经验,强化预处理方案似乎可改善Ph +急性淋巴细胞白血病患者骨髓移植的结果。然而,高复发率需要新的方法来提高抗白血病疗效。